Effects of Latrepirdine on beta amyloid clearance, aggregation and neurodegeneration in Alzheimer�s disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1009295

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Alzheimer's disease (AD) is becoming more common with our growing aged population and currently no treatment exists that halts disease progress. The increasing health costs of AD underscore the need for development of any treatment that will slow or halt AD pathogenesis. By understanding the mechanisms of action of a drug [latrepirdine] that has recently shown some promise in phase II clinical trials, related drugs that are more specific and potent will be developed.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: NHMRC Project Grants

Funding Amount: $512,647.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Biochemistry and Cell Biology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Alzheimer disease | amyloid beta-protein | biological sciences | neurodegenerative disorders | transgenic model | yeast

Related Links